What's Happening?
A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The
phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Why It's Important?
The findings of this study are significant as they offer a promising advancement in the treatment of melanoma, a common form of skin cancer in the United States. The combination of intismeran and pembrolizumab could potentially improve survival rates and reduce cancer recurrence, providing a new therapeutic option for patients. This development also underscores the potential of mRNA vaccines in cancer treatment, which could be applied to other types of cancer with high mutation rates. The study's success could lead to broader applications of personalized immunotherapy, potentially transforming cancer treatment protocols and improving patient outcomes.
What's Next?
A phase 3, multicenter trial is currently underway to evaluate the effectiveness of intismeran as a first-line therapy in combination with pembrolizumab for melanoma. The vaccine is also being tested for its potential to prevent recurrence in other cancers, such as lung cancer. The ongoing research and trials will determine the broader applicability of this combination therapy and its potential integration into standard cancer treatment regimens. The results of these trials could influence future cancer treatment strategies and lead to more personalized and effective therapies.
